张梅静,陈传军,高炬,曲涛,张萌,翟东东

• 1:北京航天中心医院心脏医学部

摘要(Abstract)：

目的 评价血细胞及其衍生物与冠心病药物涂层球囊（DCB）介入治疗预后的关系。方法 回顾性分析2016年1月至2021年12月于航天中心医院因冠心病应用DCB介入治疗的患者197例，根据介入术后1年内是否发生靶病变血运重建（TLR）进行分组，发生TLR为观察组（38例），未发生TLR为对照组（159例），比较两组患者术前血细胞及其衍生物。比较两组中性粒细胞计数/淋巴细胞计数（NLR）和血小板计数/淋巴细胞计数（PLR）的差异，并绘制NLR和PLR预测TLR的受试者工作特征曲线（ROC）。结果 两组患者治疗前一般临床特征比较差异均无统计学意义（均P>0.05），观察组与对照组相比，在DCB介入治疗前的NLR和PLR水平均显著升高，差异均有统计学意义（均P<0.05）。多因素Logistic回归分析显示，NLR(OR 0.175,95%CI0.061～0.496,P=0.001)、PLR(OR0.159,95%CI0.050～0.503,P=0.002)是预测DCB介入治疗后发生TLR的独立危险因素。PLR预测TLR的最佳截断值为140.21，敏感度为81.6%，特异度为61.0%;NLR预测TLR的最佳截断值为3.21，敏感度为84.2%，特异度为61.3%。结论 NLR、PLR升高对冠心病DCB介入术后TLR具有一定的预测价值。

关键词(KeyWords)： 药物涂层球囊;血细胞及其衍生物;靶病变血运重建

Abstract:

Keywords:

基金项目(Foundation): 中国航天科工集团公司医疗卫生科研项目（2020-LCYL-004）

作者(Author): 张梅静,陈传军,高炬,曲涛,张萌,翟东东

参考文献(References)：

• [1] Van Den Berg JC,Pedrotti M,Canevascini R,et al.Endovascular treatment of in-stent restenosis using excimer laser angioplasty and drug eluting balloons[J]. J Cardiovasc Surg(Torino),2012,53(2):215-222.
• [2] Windecker S,Kolh P,Alfonso F,et al. 2014 ESC/EACTS guidelines on myocardial revascularization:the task force on myocardial revascularization of the European Society of Cardiology(ESC)and the European Association for CardioThoracic Surgery(EACTS)developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI)[J]. Eur Heart J,2014,35(37):2541-2619.
• [3] Siontis GC,Stefanini GG,Mavridis D,et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis:a network meta-analysis[J]. Lancet,2015,386(9994):655-664.
• [4] Scheller B,Ong PJ,Kleber F. Drug-coated balloon treatment as default strategy for DES-ISR[J]. J Am Coll Cardiol,2016,67(3):346-347.
• [5] Unverdorben M,Kleber FX,Heuer H,et al. Treatment of small coronary arteries with a paclitaxel—coated ballon catheter[J].Clin Res Cardiol,2010,99(3):165-174.
• [6] Latib A,Colombo A,Castriota F,et al. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels. The BELLO(balloon elution and late loss optimization)study[J].J Am Coll Cardiol,2012,60(24):2473-2480.
• [7]翟东东，高炬，张萌，等.药物涂层球囊在冠状动脉小血管病变中的应用观察[J].中国循证心血管医学杂志，2019,11(4):477-479.
• [8]翟东东，高炬，张萌，等.药物涂层球囊在冠状动脉分支开口病变中的应用[J].中国介入心脏病学杂志，2017,25(7):390-394.
• [9] Tian J,Tang YD,Qiao S,et al. Two-year follow-up of a randomized multicenter study comparing a drug-coated balloon with a drug-eluting stent in native small coronary vessels:the RESTORE small vessel disease China trial[J]. Catheter Cardiovasc Interv,2020,95 Suppl 1:587-597.
• [10] Alfonso F,Pérez-Vizcayno MJ,Cárdenas A,et al.A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents:the RIBSⅣrandomized clinical trial[J]. J Am Coll Cardiol,2015,66(1):23-33.
• [11] Afari ME,Bhat T. Neutrophil to lymphocyte ratio(NLR)and cardiovascular diseases:an update[J]. Expert Rev Cardiovasc Ther,2016,14(5):573-577.
• [12] Jeger RV,Eccleshall S,Ahmad WAW,et al. Drugc o a t e d balloons for coronary artery disease:third report of the International DCB Consensus Group[J].JACC Cardiovasc Interv,2020,13(12):1391-1402.
• [13]柯元南，陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志，2007,35(4):295-304.
• [14]陈韵岱，王建安，刘斌，等.药物涂层球囊临床应用中国专家共识[J].中国介入心脏病学杂志，2016,24(2):61-67.
• [15] Valgimigli M,Bueno H,Byrne RA,et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS:the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology(ESC)and of the European Association for Cardio-Thoracic Surgery(EACTS)[J]. Eur Heart J,2018,39(3):213-260.
• [16]张爽，赵守军，李彩霞，等.诊断试验最佳截断值的估计方法[J].中国疫苗和免疫，2009,15(5):475-476,480.
• [17] Cremers B,Toner JL,Schwartz LB, et al.Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter[J]. Clin Res Cardiol,2012,101(6):469-476.
• [18] Loh JP,Barbash IM,Waksman R.The current status of drugcoated balloons in percutaneous coronary and peripheral interventions[J].Euro Intervention,2013,9(8):979-988.
• [19] Shlofmitz E,Iantorno M,Waksman R. Restenosis of drugeluting stents[J]. Circ Cardiovasc Interv,2019,12(8):e007023.
• [20] Tanaka A,Latib A,Jabbour RJ,et al. Impact of angiographic result after predilatation on outcome after drug-coated balloon treatment of in-stent coronary restenosis[J]. Am J Cardiol,2016,118(10):1460-1465.
• [21] Cassese S,Byrne RA,Schulz S,et al. Prognostic r o l e of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting[J]. Eur Heart J,2015,36(2):94-99.
• [22] Qin SY,Zhou Y,Jiang HX,et al. The association of diabetes mellitus with clinical outcomes after coronary stenting:a metaanalysis[J]. PLoS One,2013,8(9):e72710.
• [23] Rittger H,W?hrle J,Brachmann J,et al. Angiographic patterns of drug-eluting stent restenosis after treatment with drug-coated balloon versus balloon angioplasty:late lumen loss subgroup analyses of the PEPCAD-DES study[J]. Catheter Cardiovasc Interv,2016,88(4):529-534.
• [24] Giannini F,Latib A,Jabbour RJ,et al. Comparison of paclitaxel drug-eluting balloon and paclitaxel-eluting stent in small coronary vessels in diabetic and nondiabetic patients-results from the BELLO(balloon elution and late loss optimization)trial[J]. Cardiovasc Revasc Med,2017,18(1):4-9.
• [25]杨铮，黄萍，杨阳，等.血脂和脂蛋白水平与2型糖尿病并发血管病变的关系[J].中国慢性病预防与控制，2016,24(1):38-40.
• [26]邢健，陈少伯.糖化血红蛋白与冠心病并2型糖尿病患者冠状动脉病变复杂程度的关系研究[J].实用心脑肺血管病杂志，2018,26(8):22-27.
• [27]王莹，陈剑通，郭阳.中性粒细胞和淋巴细胞比值与动脉粥样硬化研究进展[J].医学研究生学报，2018,31(5):550-554.
• [28]谢灵芝，郑青，陈宁琳. 2型糖尿病并发冠心病患者中性粒细胞/淋巴细胞比值的变化及意义[J].江苏医药，2018,44(2):185-188.
• [29] Winkler K,Winkelmann BR,Scharnagl H,et al. Plateletactivating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic infl ammation and other risk factors:the Ludwigshafen risk and cardiovascular health study[J]. Circulation,2005,111(8):980-987.
• [30] Costa MA,Simon DI. Molecular basis of restenosis and drug eluting stents[J]. Circulation,2005,111(17):2257-2273.
• [31] Wang Z,Liu C,Fang H. Blood cell parameters and predicting coronary in-stent restenosis[J]. Angiology,2019,70(8):711-718.
• [32] Spark JI,Sarveswaran J,Blest N,et al. An elevated neutrophil-lymphocyte ratio independently predicts mortality in chronic critical limb ischemia[J]. J Vasc Surg,2010,52(3):632-636.
• [33] Gabbasov Z,Kozlov S,Byazrova S,et al. Blood level of CD45+platelets and development of restenosis after drug-eluting stent implantation in patients with stable coronary artery disease[J].Wien Klin Wochenschr,2016,128(23-24):898-905.
• [34] Li C,Shen Y,Xu R,et al. Evaluation of preprocedural laboratory parameters as predictors of drug-eluting stent restenosis in coronary chronic total occlusion lesions[J]. Angiology,2019,70(3):272-278.
• [35] Balta S,Celik T,Mikhailidis DP,et al. The relation between atherosclerosis and the neutrophil-lymphocyte ratio[J]. Clin Appl Thromb Hemost,2016,22(5):405-411.
• [36] Nikolsky E,Grines CL,Cox DA,et al. Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction(from the CADILLAC trial)[J]. Am J Cardiol,2007,99(8):1055-1061.
• [37] Dam?s JK,Waehre T,Yndestad A,et al. Interleukin-7-mediated inflammation in unstable angina:possible role of chemokines and platelets[J]. Circulation,2003,107(21):2670-2676.
• [38] Yilmaz S,Sen F，ünal S,et al. Usefulness of the platelet-tolymphocyte ratio in predicting bare-metal stent restenosis[J].Scand Cardiovasc J,2015,49(1):39-44.
• [39] Neumann FJ,Sousa-Uva M,Ahlsson A,et al.2018 ESC/EACTS guidelines on myocardial revascularization[J]. Kardiol Pol,2018,76(12):1585-1664.
• [40]周玉杰，刘巍. 2018年欧洲心脏协会和欧洲心胸外科协会血运重建指南解读[J].中国介入心脏病学杂志，2018,26(9):497-500.